GleamWall
中文EN

BRVE Braveheart Bio, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 2131524 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY—
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA—
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets3.3%
Debt / equity0.00x
Current ratio21.57x
Interest coverage—

Cash quality & payout

Operating cash flow / net income—
Accruals ratio—
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q32025-09-302025Q22025-06-302025Q12025-03-31
Income statement
Revenue——————
R&D expense$17.54M$11.12M—$9,000$0—
SG&A expense$12.61M$4.76M—$508,000$27,000—
Operating income-$30.15M-$15.88M—-$59.29M-$381,000—
Net income-$26.50M-$14.99M-$14.28M-$59.12M-$381,000-$99,000
EBITDA-$30.15M——-$59.29M——
EPS (basic)-0.51-2.51—-10.05-0.14—
EPS (diluted)-0.51-2.51—-10.05-0.14—
Weighted avg. shares (diluted)52.10M7.40M—5.88M2.79M—
Balance sheet
Cash & equivalents$121.29M$122.83M—$67.53M$2,000—
Current assets$359.57M$123.44M————
PP&E, net$20,000$23,000————
Total assets$514.45M$126.96M————
Current liabilities$16.67M$9.06M————
Total liabilities$16.85M$9.34M————
Shareholders' equity$497.60M-$95.91M-$78.39M-$59.59M-$477,000-$99,000
Shares outstanding82.07M7.54M————
Cash flow statement
Operating cash flow-$24.37M——-$740,000——
Capital expenditure$0——$0——
Free cash flow-$24.37M——-$740,000——
Investing cash flow-$382.45M——-$32.73M——
Financing cash flow$405.28M——$101.00M——
Depreciation & amortization$3,000——$0——
Stock-based compensation$2.79M——$0——

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.